TWST240719C37500
- 12.60
- 0.000.00%
Twist Bioscience Newsroom
Ark's Cathie Wood Blasts Big Tech. She Prefers Palantir and These Other Stocks.
Cathie Wood's flagship ARK Innovation exchange-traded fund is 72% below its peak while the S&P 500 is hitting all-time highs.
Twist Bioscience to Report Fiscal 2024 Third Quarter Financial Results on Friday, August 2, 2024
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today
Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates
In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company's flagship fund, ARK Innovation ETF (NYSE:ARKK), despite its recent underperformance.
Express News | Twist Bioscience Expands High-Throughput Igg Antibody Portfolio With Launch of Cho Express Antibodies
Goldman Sachs Raises Price Target on Twist Bioscience to $55 From $45, Maintains Buy Rating
Twist Bioscience (TWST) has an average rating of outperform and price targets ranging from $28 to $65, according to analysts by Capital IQ.Price: 48.88, Change: -0.08, Percent Change: -0.15
Twist Bioscience Price Target Raised to $55.00/Share From $45.00 by Goldman Sachs
Twist Bioscience Price Target Raised to $55.00/Share From $45.00 by Goldman
Twist Bioscience Is Maintained at Buy by Goldman Sachs
Twist Bioscience Is Maintained at Buy by Goldman
Goldman Sachs Maintains Buy on Twist Bioscience, Raises Price Target to $55
Goldman Sachs analyst Matthew Sykes maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $45 to $55.
Twist Bioscience Expands Synthetic Viral Controls Portfolio With Launch Of Synthetic RNA Control For H5N1 Influenza A; Covers 99.9% Of Hemagglutinin And Neuraminidase Genome Regions
Twist Bioscience Expands Synthetic Viral Controls Portfolio With Launch Of Synthetic RNA Control For H5N1 Influenza A; Covers 99.9% Of Hemagglutinin And Neuraminidase Genome
Express News | Twist Bioscience Corp - Ngs-Verified Synthetic Control Covers 99.9% of Ha and NA Genome Regions
Express News | Twist Bioscience Launches Synthetic Rna Control for H5N1 Influenza a
We're Not Worried About Twist Bioscience's (NASDAQ:TWST) Cash Burn
Just because a business does not make any money, does not mean that the stock will go down. For example, Twist Bioscience (NASDAQ:TWST) shareholders have done very well over the last year, with the
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
On Tuesday, Cathie Wood-led Ark Invest made significant adjustments to its portfolio, offloading a substantial number of shares in Tesla Inc (NASDAQ:TSLA) and scooping up a hefty stake in Palantir Tec
Is Twist Bioscience Corporation (TWST) a Good Stock to Buy and Hold for 5 Years?
Form 144 | Twist Bioscience(TWST.US) Officer Proposes to Sell 906.74K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Twist Bioscience(TWST.US)$ Officer Banyai William intends to sell 18,777 shares of its common stock on Jul 1, with a total market value of approximately $906.74K. Ban
Twist Bioscience Is Maintained at Overweight by Barclays
Twist Bioscience Is Maintained at Overweight by Barclays
Express News | Twist Bioscience : Barclays Raises Target Price to $60 From $45
Barclays Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $60
Barclays analyst Luke Sergott maintains $Twist Bioscience(TWST.US)$ with a buy rating, and adjusts the target price from $45 to $60.According to TipRanks data, the analyst has a success rate of 40.5%
Here's Why We're Not At All Concerned With Twist Bioscience's (NASDAQ:TWST) Cash Burn Situation
Twist Bioscience Is Maintained at Buy by TD Cowen
Twist Bioscience Is Maintained at Buy by TD Cowen